Treatment modalities of skeletal involvement in prostate cancer patients
Authors:
V. Vít
Authors place of work:
Urologická klinika FN Brno
Published in the journal:
Urol List 2009; 7(4): 27-30
Summary
The author deals with the issue of metastatic prostate cancer and treatment of bone dissemination, which significantly disrupts patient´s quality of life (mainly in the form of serious skeletal related events). Author evaluates the impact of bisfosfonates therapy (zoledronic acid in particular) on quality of life. Despite definite data recommending bisfosfonates therapy as an integral part of palliative treatment in patients with disseminated prostate carcinoma is their use in clinical practice very infrequent. The aim of this article is to present an overview of bisfosfonates therapy benefits in disseminated prostate cancer treatment and a body of recommendations based on EBM (Evidence Based Medicine), which may help to promote a wide-spread usage of bisfosfonates in clinical practice.
Key words:
prostate cancer, bone dissemination, bisfosfonates, zoledronic acid
Zdroje
1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3): 581–592.
2. Údaje NOR na www.svod.cz.
3. Carlin BI, Andriole GL. The natural history, skeletal complications and management of bone metastase in patient with prostate cancer. Cancer 2000; 88(9): 2989–2994.
4. Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer. J Neurooncol 1995; 23(2): 135–147.
5. Smith JA. Palliation of Painful Bone Metastases from Prostate Cancer using Sodium Etidronate: Results of a Randomized, Prospective, Double-blind, Placebo-controlled Study. J Urol 1989; 141(1): 85–87.
6. Elomaa I et al. Effect of Oral Clodronate on Bone Pain. A Controlled Study in Patients with Metastatic Prostate Cancer. Int Urol Nephrol 1992; 24(2): 159–166.
7. Strang P et al. The Analgesic Efficacy of Clodronate Compared with Placebo in Patients with Painful Bone Metastases from Prostatic Cancer. Anticancer Res 1997; 17(6D): 4717–4721.
8. Kylmäla T et al. Concomitant i.v. and oral clodronate in the relief of bone pain – a double-blind, placebo-controlled study in patients with prostate cancer. Br J Cancer 1997; 76(7): 939–942.
9. Ernst DS et al. Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain. J Clin Oncol 2003; 21(17): 3335-3342.
10. Small EJ et al. Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer. J Clin Oncol 2003; 21(23): 4277–4284.
11. Saad F et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patiens with metastatic hormon-refractory prostate cancer. Journal of the National Cancer Institute 2004; 96(11): 879–882.
12. Ullen A, Lennartsson L, Harmenberg U et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 2005; 44(6): 644–650.
13. Heidenreich A et al. EAU Guidelines on Prostate Cancer; EAU 2008.
14. National Comprehensive Cancer Network, VI 2008. Clinical Practice guidelines in oncology. Prostate Cancer 2008.
15. The British Association of Urological Surgeons. Systemic Management of Metastatic Bone Disease; Guidelines on treatment 2005.
16. Caroll PR. Management of disseminated prostate cancer. In: Denis L et al.:Eds Prostate Cancer: 3rd Intern. Consultation on Prostate Cancer, Paris, 2003, 251.
17. Aapro M et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19(3): 420–432.
18. Základy cytostatické léčby maligních onkologických onemocnění. Česká onkologická společnost ČLS JEP, 9.vydání, 2009.
19. Katolická J. Využití bisfosfonátů v léčbě karcinomu prostaty. Farmakoterapie 2008; 5: 517–521.
20. Matoušková M, Hanuš T. Bisfosfonáty v léčbě kostních metastáz v urologii. Urologie pro praxi. 2009; 5: 282–286.
21. Pavlík I. Podávání bisfosfonátů u pacientů s karcinomem prostaty metastazujícím do kostí. Farmakoterapie 2007; 2: 6–11.
22. Belej K, Kaplan O. Možnosti systémové léčby karcinomu prostaty. Urologie pro Praxi 2009; 3: 168–174.
Štítky
Paediatric urologist UrologyČlánok vyšiel v časopise
Urological Journal
2009 Číslo 4
Najčítanejšie v tomto čísle
- Intraoperational course, early complications and functional outcome in robotic-assisted AND OPEN RADICAL PROSTATECTOMY – A COMPARISON
- SURGICAL ANATOMY OF THE PROSTATE & PELVIC FLOOR FOR THE PERFORMANCE OF RADICAL PROSTATECTOMY & RADICAL CYSTECTOMY: CRITICAL POINTS FOR ACHIEVING THE TRIFECTA OF ONCOLOGIC SAFETY, URINARY CONTROL, AND ERECTILE FUNCTION
- ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY: A CRITICAL ASSESSMENT OF OUTCOMES
- TRANSITION OF WHOLE GLAND CRYOSURGERY TO FOCAL CRYOABLATION FOR THE TREATMENT OF EARLY STAGE LOCALIZED PROSTATE CANCER